Revista Peruana de Reumatología: Volumen 2 Nº 2, Año 1996 LIMA-PERÚ


1. Tatal N, Fye K. Moutosopoulos HM Autoinmunity. Fundenberg H.H. Basic &  clinical immunology, 2.ª de los altos California 1978.

2.  Yoshida S, Gershwin M.E. Autoinmunity and Selected Environmental Factors of Disease Induction. Sem. Arthr. Rheum. June 1993; 22: 6, 399-419.

3. Klemetti E, Collin HL, Forss H, Markkanen H, Lassila V. Mineral status of     skeleton and advanced periodental disease. J-Clin-Periodontol. Mar 1994;    21(3): 1848.

4. Gilman SC, Chang J, Zeigler PR. Interleukin-I activates phospholipase A2 in human synovial. Arthritis Rheum 1988; 31: 126-1230.

5. Brennan FM, Chantry D, Jackson A. Inhibitory effect of TNF ä antibodies on synovial cell interleukin I production in rheumatoid arthritis. Lancet 1989; 2: 244-247.

6. Robinson DR, Tashjain AH Jr, Levine L. Prostaglandin-stimulated bone resorption by rheumatoid synovia. J Clin Invest 1975; 56: 1181-1188.

7. Chesney RW, Mazess RB, Hamstra AJ: Reduction of serum 1,25-dihydrixyvitamin D in children receiving glucorticoids. Lancet 1978; 2: 1123-1125.

8. Harn TJ, Halstead LR, Teitelbaunm SL. Altered Mineral Metabolism in glucocorticoid induced osteopenia: Effect of 25-hydroxyvitamin D administration. J Clin Invest 1979; 64: 655-665.

9. Adachi JD, Bensen WG, Hodsman AB: Corticosteroid-Inducid Osteoporosis. Semin Arth Rheum 1993; 22: N.º6, 375: 384.

10. Warady BD, Lindsley CB, Robinson FG, Lukert BP. Effects of nutritional suplementation on bone mineral status of children with rheumatic diseases receiving corticosteroid therapy. J-Rheumatol Mar 1994; 21(3): 530-5.

11. Harris DE Jr. Mechanisms of disease: Reumatoid arthritis-pathophysiology and implications for therapy. NEJM 1990; 322: 1277-1289.

12. Marbach JJ, H. Rheumatoid arthritis of temporomandibular joints. Ann Rheum Dis1967; 26: 538-54.

13. Kahan BD. Cyclosporine. N Engl J Med 1989; 321: 1725-1738.

14. Cohen DJ, Apple GB. Cyclosporine Ñ Nefrotoxic Effects and Guidelines for Safe Use in Patients with Rheumatoid Arthritis. Semin. Arthr. Rheum June 1992; 21: 6, suppl 343-48.

15. Tugwell P. Cyclosporine in Rheumatoid Arthritis: Documented Efficacy and Safety. Semin. Arthritis Rheum, june 1992; 21: 6, suppl 3, 30-38.

16. Rothermich N, Whisler R, Antimalarials. Reumatoid Arthritis Grune & Stratton, Inc. USA, 1985.

17. Husby Gunnar. Amyloidosis. Semin Arthritis Rheum 1992; 22: 67-82.

18. Karhulahti T, Ylijoki H, Ronning O. Mandibular condylelesions related to age at onset and subtypes of juvenile rheumatoid arthritis in 15-year-old children. Scand-J-Dent-Res. Oct 1993; 101(5): 332-8.

19. Ronning O, Barnes SA, Pearson MH, Pledger DM. Juvenile chronic arthritis: a cephalometric analysis of the facial skeleton: Eur-J-Orthod. 16(1): 53-62 Feb 1994 Wallace CA, Bleyer WA, Sherry DD, Salmonson KL, Wedgwood RJ. Toxicity and serum levels of methotrexate in children with juvenile rheumatoid Arthritis. Arthr Rheum, june 1989; 32: 6, 677-681.

20. Oxholm P. Primary Sjögren's Syndrome Clinical and Laboratory Markers of Disease Activity. Senin Arthritis Rheum 1992; 22: 114-126.

21. Vitali C, Tavoni A, Simi U, et al: Parotid sialography and minor salivary gland biopsy in the diagnosis of Sjögren's syndrome. A comparative study of 84 patients. J Rheumtol 1988; 15: 262-267.

22. Koffler D, Agnello V, Thoburn R. Systemic lupus erythematosus prototype of inmune complex disease in man. J Exp Med 1971; 134, 169.

23. Guilian JN, Sontheinmer RD. Distinctive cutaneos subset in the spectrum of lupus erythematosus. J Am Acad Dermatol 1981; 4: 471-475.

24. Urman JD, Lowestein MB, Abeles M and Weinstein A. Oral mucosal ulceration in systemic lupus erythematosus. Arthr, Rheum 1978; 21: 58-61.

25. Pistiner M, Wallace DJ, Nessim S, Metzeger AL and Klinenberg JR: Lupous erythematosus in 1980s: A survey of 570 patients Semin Arthritis Rheum 1991; 21: 55-64.

26. Laman SD, Provost TT. Cutaneus Manifestations of Lupus Erythematosus Feb. 1994; 20: 1, 197-212.

27. Gómez J, Palazón D, Ortega G, Lucas E, Bru M, Campillo M, Torralba M, y col. Infecciones y lupus eritematoso Sistémico. Análisis de factores de riesgo y pronóstico. Estudio prospectivo (1979-1988) Rev. Clin. Esp. 1991; 188: 72-75.

28. Leroy EC, Silver E. Systemic esclerosis and related syndromes. Ralph Schumaker. Primer on the Rheumatic Diseases Tenth Edition. Arthritis Foundation, Atlanta, Georgia, 1993.

29. Greenberg MS. Enfermedades inmunológicas. Medicina Bucal, Lynch M.A. Interamericana tercera edición 1980.

30. White SC. Oral radiographic changes in patients with progresive sclerosis (scleroderma). J Am Dent Assoc 1977; 94: 1178

31. Plotz PH, Leff RL, Miller FW. Inflamatory an metabolic myopathies. Primer on the Rheumatic Diseases Tenth Edition H. Ralph Schumaker. 1993; 127-131.

32. Conn DL. Update on Systemic Necrotizing Vasculitis Mayo-Clin Proc. May 1989; 64: 535-543.

33. Falk RJ, Jennette JC. Antineutrophil Cytoplasmic Autoantibodies with Specificity for Myeloperoxidase in Patients with Systemic Vasculitis and Idiopathic Necrotizing and Crescentic Glomerulonephritis: N-Engl-J-Med. June 23 1988; 318: 1651-1657.

34. Travis WD, Carpenter HA, Lie JT. Diffuse Pulmonary Hemorrhage: An Uncommon Manifestation of wegener's Granulomatosis, Am J Surg Pathol. September 1987; 11: 702-708.

35. International Study Group for Behçet Disease: Criteria for diagnosis of Behçet disease. Lancet 1990; 335: 1078-1080.

36. Donnelly S, Jothy S, Barre P. Crescentic Glomerulonephritis in Behçet's Syndrome: Results of Therapy and Review of the Literature Clin Nephrol. April 1989; 31: 213-218.

Regresar al Artículo